Waltham, MA. NeuroMetrix is developing a new class of non-invasive products for point-of-care testing of neuromuscular disorders. The company’s technology provides physicians with immediate and cost-effective information to be used as an aid in the diagnosis of common neuromuscular conditions. The company went public in 2004 (NASDAQ: NURO).
Investment Partners: BancBoston Ventures, Delphi Ventures, Harris & Harris Group, Massachusetts Institute of Technology, Whitney & Co.
